Correction to: Effcacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study

Affiliations

• ¹ Department of Dermatology, School of Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, 197, Rui Jin Er Road, Shanghai, 200025, China.
• ² Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China.
• ³ Department of Dermatology, Peking University Third Hospital, Beijing, China.
• ⁴ Department of Dermatology, Jiangsu Province People's Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, China.
• ⁵ Department of Dermatology, The Second Norman Bethune Hospital of Jilin University, Jilin, China.
• ⁶ Department of Dermatology, Zhejiang Provincial People's Hospital, Zhejiang, China.
• ⁷ Department of Dermatology, First Hospital of Shanxi Medical University, Shanxi, China.
• ⁸ Eli Lilly and Company, Shanghai, China.
• ⁹ Department of Dermatology, School of Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, 197, Rui Jin Er Road, Shanghai, 200025, China. [email protected].